A Phase 2 interventional study of Daunorubicin and Cytarabine in Acute Myeloid Leukemia (AML), sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute — 11 open to participants now, 16 under way, 4 of them phase 3. Daunorubicin · Leukemia, Myeloid, Acute.
Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, this one is the 15th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 13 of the 15 other live ones, and was the 49th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →11 of the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Kura Oncology, Inc. · Sites in United States, Australia, Belgium and 14 more countries
Ages 18+
Richard Stone, MD · Sites in United States
Ages 18–75
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18–59
By country, each count listing its studies:
Daunorubicin: first FDA approval 1979 (CERUBIDINE), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 23 · Phase 3 14 · Phase 4 1
First in 1998; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 111 across the 48 interventional studies. Of the 29 that completed or were terminated, 11 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 50 have an industry lead sponsor. The 10 most frequent:
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 413 studies on the registry; 291 are open to participants now.
46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China: 29 open now, 32 under way, 5 of them phase 3. Of 9 finished, 0 (0%) have results posted.
Among the 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China, this one is the 3rd largest by planned enrollment of the 41 interventional ones that give a count, is one of 10 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 28 of the 31 other live ones, and was the 43rd registered.
Institute of Hematology & Blood Diseases Hospital, China’s Leukemia, Myeloid, Acute studies by the year they started, since 2005.
4 of the studies testing daunorubicin in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07561892Fujian Medical University Union HospitalStudy of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). | 2026-12-31 |
| NCT04801797Massachusetts General HospitalVenetoclax + Azacitidine vs. Induction Chemotherapy in AML | 2027-01-01 |
| NCT06313437Richard Stone, MDRevumenib in Combination With 7+3 + Midostaurin in AML | 2027-03-02 |
| NCT05554406National Cancer Institute (NCI)Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, from their registry updates:
Among Institute of Hematology & Blood Diseases Hospital, China’s 46 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
This randomized, open label, multi arm phase II trial will evaluate the efficacy and safety of venetoclax based induction regimens of varying intensity (VA, VAM, or 2+5+V) versus standard 3+7 in fit patients aged ≥14 years with newly diagnosed AML. The trial is designed to select the optimal regimen as the experimental arm for a subsequent phase III randomized controlled trial.
A total of 320 patients will be enrolled in this study,and segregated into four groups with 80 in each group. Patients who achieve CR/CRi/CRh after using different induction regimens will receive the same consolidation. Allogeneic hematopoietic stem cell transplantation is recommended for patients in the high-risk group or those with persist MRD positivity. After completion of the treatment phase, patients entered the follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the following laboratory test requirements (assessed within 7 days prior to treatment):
Exclusion Criteria:
Active cardiac disease, defined as one or more of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: daunorubicin daunorubicin: 60 mg/m2, administered by intravenous drip (ivgtt) on days 1-3, Drug: Cytarabine Cytarabine: 100 mg/m2, administered by intravenous drip (ivgtt) on days 1-7,
Drug: Daunorubicin · Drug: Cytarabine
Drug: Liposome Mitoxantrone Liposome Mitoxantrone: 24 mg/m², administered by intravenous drip (ivgtt) on day 1, every 4 weeks Drug: Venetoclax Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14, administered orally (po), every 4 weeks Drug: Azacitidine Azacitidine: 75 mg/m², administered subcutaneously (sc) on days 1-7,
Drug: Liposome Mitoxantrone · Drug: Venetoclax · Drug: Azacitidine
Drug: Venetoclax Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-21, administered orally (po). Bone marrow examination is performed on day 21. If blasts \>5%, then venetoclax 400 mg is continued on days 21-28. Drug: Azacitidine Azacitidine: 75 mg/m², administered subcutaneously (sc) on days 1-7,
Drug: Azacitidine · Drug: Venetoclax
Drug: daunorubicin daunorubicin: 60 mg/m2, administered by intravenous drip (ivgtt) on days 1-2, every 4 weeks Drug: Cytarabine Cytarabine: 100 mg/m2, administered by intravenous drip (ivgtt) on days 1-5, every 4 weeks Drug: Venetoclax Venetoclax: 100 mg on day 3, 200 mg on day 4, and 400 mg on days 5-11, administered orally (po)
Drug: Daunorubicin · Drug: Cytarabine · Drug: Venetoclax
daunorubicin: 60 mg/m2, administered by intravenous drip (ivgtt) on days 1-3,
Cytarabine: 100 mg/m2, administered by intravenous drip (ivgtt) on days 1-7,
Liposome Mitoxantrone: 24 mg/m², administered by intravenous drip (ivgtt) on day 1,
Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14, administered orally (po),
Azacitidine: 75 mg/m², administered subcutaneously (sc) on days 1-7,
Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-21, administered orally (po). Bone marrow examination is performed on day 21. If blasts \>5%, then venetoclax 400 mg is continued on days 21-28.
daunorubicin: 60 mg/m2, administered by intravenous drip (ivgtt) on days 1-2,
Cytarabine: 100 mg/m2, administered by intravenous drip (ivgtt) on days 1-5,
Venetoclax: 100 mg on day 3, 200 mg on day 4, and 400 mg on days 5-11, administered orally (po),
Event-free survival (EFS)
It is defined as the time from the start of randomization to the occurrence of induction failure or disease progression or death from any cause (whichever occurs first).
Time frame: up to 3 years
30-day postinduction mortality
It is defined as death from any cause within 30 days after the start of induction.
Time frame: up to 30 days
60-day postinduction mortality
It is defined as death from any cause within 60 days after the start of induction.
Time frame: Up to 60 days
Composite complete remission (CRc) rate
Proportion of patients with complete remission (CR), complete remission with partial hematologic recovery (CRh) or complete remission with incomplete hematologic recovery (CRi).
Time frame: Up to eight weeks
Measurable Residual Disease (MRD) negative rate by flow cytometry
Among those who have achieved CR/CRh/CRi after induction, proportion of patients who is MRD-negative by flow cytometry.
Time frame: Up to eight weeks
Measurable Residual Disease (MRD) negative rate by molecular testing
Among those who have achieved CR/CRh/CRi after induction, proportion of patients who is MRD-negative by molecular testing.
Time frame: Up to approximately eight weeks
Relapse-free Survival (RFS)
It is defined as the time from the start of achieving remission to disease progression, death from any cause or the last follow-up.
Time frame: Up to 3 years
Overall survival (OS)
It is defined as the time from the start of randomization to the death from any cause.
Time frame: Up to 3 years
Cumulative incidence of relapse (CIR)
It is defined as the time from the start of achieving remission to hematologic relapse.
Time frame: Up to 3 years
Incidence of treatment related adverse events
The safety of the drug was evaluated by NCI-CTC AE 5.0 standard which including hematologic and non-hematologic toxicity.
Time frame: From day 1 of treatment to 28 days after the last dose
No study locations are listed for this record.
Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.
Of 386 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 36 months is below that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daunorubicin · Cytarabine · Venetoclax
Institute of Hematology & Blood Diseases Hospital, China →